News

Friday Policy Updates – 1/5/2018

Under the Gold Dome – The 71st General Assembly


The 2018 Colorado Legislative session begins next Wednesday, January 10th! The CBSA team will be busy advocating on behalf of the Colorado Bioscience industry and our members.Be sure to check the weekly policy blog to get ongoing updates regarding happenings during the legislative session. We continue focus on sharing firsthand the value of our industry with elected officials and reinforcing bioscience as a key industry in the State. To learn about the Colorado BioScience Association’s state and policy priorities click here. We encourage you to get involved in policy and let us know what matters to you and your business!

This week, the CBSA team attended the Denver Metro Chamber of Commerce’s Business Legislative Preview event to hear firsthand from leadership about their priorities for the upcoming legislative session. For a Denver Business Journal recap of the event click here.And to learn more about key priorities for the House speaker and Senate president for this upcoming legislation session and what it looks like to have session with an upcoming election click here.

SAVE THE DATE for the 2018 Colorado Bioscience Association Day at the Capitol event on Wednesday, February 7th. For more information and to register click here.

Repealing the Medical Device Excise Tax

Repealing the Medical Device Excise Tax continues to be a top priority for CBSA and Colorado’s med tech innovators. No stone is being unturned in this effort. CBSA and member companies continue to send letters to the entire Colorado Congressional Delegation. In our most recent letter (click here to view) we urge Congress to take immediate action to address the medical device tax now that it has become law, and is unfortunately already stifling innovation and patient care. Thank you to our members who have stepped up to let your elected official know the consequences this tax has on our industry.

POLITICO’S PULSE CHECK – FDA Commissioner Scott Gottlieb (Podcast)

Many would agree that it has been a busy and productive year for the FDA under the leadership of Commissioner Scott Gottlieb.Over the past year we have seen many positive steps for our industry.In fact it is reported by Fortune and FierceBiotech that 2017 saw the most new drugs approved in over 20 years.

Listen to a podcast from POLITICO’s Pulse Check where they discuss with Commissioner Scott Gottlieb the agency’s work over the past year, why he took the job and what lies ahead in 2018!


 




Go Back